GART: A Potential Drug Target for Neurodegenerative Diseases (G2618)
GART: A Potential Drug Target for Neurodegenerative Diseases
GART (GART variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a critical role in cellular signaling.
GART has been identified as a potential drug target due to its unique structure and the various functions that it is known to regulate. One of the most promising aspects of GART is its ability to interact with several different signaling pathways, including those involved in neurotransmitter release, neuropeptide signaling, and stress response.
GART has also been shown to play a role in several diseases and disorders, including neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Studies have suggested that GART may be a useful target for these conditions, as blocking its activity may offer new treatments for these debilitating diseases.
In addition to its potential as a drug target, GART has also been shown to be a valuable biomarker for several diseases. The GART protein is expressed in a variety of tissues and can be used as a protein biomarker for diseases such as neurodegenerative disorders, hypertension, and diabetes.
GART has also been shown to play a role in several physiological processes that are important for human health, including the regulation of pain, inflammation, and stress response. It has been shown to interact with several different signaling pathways, including those involved in neurotransmitter release and stress response.
GART has also been shown to be involved in several different signaling pathways that are important for human health. One of the most promising aspects of GART is its ability to interact with several different signaling pathways, including those involved in neurotransmitter release, neuropeptide signaling, and stress response.
GART has also been shown to play a role in several diseases and disorders, including neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Studies have suggested that GART may be a useful target for these conditions, as blocking its activity may offer new treatments for these debilitating diseases.
In addition to its potential as a drug target and biomarker, GART has also been shown to have several potential therapeutic applications in other areas. For example, GART has been shown to play a role in the regulation of pain, and may be a useful target for treating chronic pain. It has also been shown to interact with the immune system, and may be a useful target for treating autoimmune diseases.
GART is a protein that has been identified as a potential drug target due to its unique structure and the various functions that it is known to regulate. Its ability to interact with several different signaling pathways makes it an attractive target for a variety of diseases and disorders. Further research is needed to fully understand the potential of GART as a drug and biomarker.
Protein Name: Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylami
Functions: Trifunctional enzyme that catalyzes three distinct reactions as part of the 'de novo' inosine monophosphate biosynthetic pathway
The "GART Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GART comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
GAS1 | GAS1RR | GAS2 | GAS2L1 | GAS2L2 | GAS2L3 | GAS5 | GAS6 | GAS6-AS1 | GAS7 | GAS8 | GAS8-AS1 | GASAL1 | GASK1A | GASK1B | GASK1B-AS1 | GAST | GATA1 | GATA2 | GATA2-AS1 | GATA3 | GATA3-AS1 | GATA4 | GATA5 | GATA6 | GATA6-AS1 | GATAD1 | GATAD2A | GATAD2B | GATB | GATC | GATD1 | GATD1-DT | GATD3 | GATM | GATOR1 Complex | GAU1 | GBA1 | GBA2 | GBA3 | GBAP1 | GBE1 | GBF1 | GBGT1 | GBP1 | GBP1P1 | GBP2 | GBP3 | GBP4 | GBP5 | GBP6 | GBP7 | GBX1 | GBX2 | GC | GCA | GCAT | GCC1 | GCC2 | GCC2-AS1 | GCDH | GCFC2 | GCG | GCGR | GCH1 | GCHFR | GCK | GCKR | GCLC | GCLM | GCM1 | GCM2 | GCN1 | GCNA | GCNT1 | GCNT1P3 | GCNT2 | GCNT3 | GCNT4 | GCNT7 | GCOM1 | GCSAM | GCSAML | GCSAML-AS1 | GCSH | GCSHP3 | GCSIR | GDA | GDAP1 | GDAP1L1 | GDAP2 | GDE1 | GDF1 | GDF10 | GDF11 | GDF15 | GDF2 | GDF3 | GDF5 | GDF6
